Study ‘Confirms Economic Viability’ of Orphan Drugs
September 24, 2012
Orphan drugs achieved blockbuster status in 2011, generating over $50 billion, and have the potential to generate as much lifetime revenue as drugs used for more common health conditions, according to a report from Thomson Reuters’ IP & Science division.